Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging drugs for the treatment of chronic myelomonocytic leukemia.

Expert opinion on emerging drugs - 1 Dec 2020

Ramos Perez Jorge, Montalban-Bravo Guillermo

Abstract excerpt

Introduction: Chronic myelomonocytic leukemia (CMML) is a clonal hematologic disorder with heterogenous prognosis, but with no curative therapies with exception of allogeneic transplant. Therapeutic options for patients with CMML are limited, and although hypomethylating agents such as azacitidine and decitabine are the standard of care, only 40% of patients achieve a response, and most responses are transient....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Design
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myelomonocytic, Chronic

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 33280448
DOI: 10.1080/14728214.2020.1854224

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging drugs for the treatment of chronic myelomonocytic leukemia.PMID 33280448Read ↗

Novel therapeutic targets for chronic myelomonocytic leukemia.Semantic proximity Read ↗

Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.Semantic proximity Read ↗

Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms.Semantic proximity Read ↗

Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.Semantic proximity Read ↗

Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment.Semantic proximity Read ↗

Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.Semantic proximity Read ↗

Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.Semantic proximity Read ↗

Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovationsSemantic proximity Read ↗

How I diagnose and treat chronic myelomonocytic leukemia.Semantic proximity Read ↗

Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid LeukemiaSemantic proximity Read ↗

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.Semantic proximity Read ↗

[Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.